Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 2-dose versus 3-dose combined hepatitis A/hepatitis B vaccination in healthy children
2015-001515-12Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hepatitis A + hepatitis B vaccine and hepatitis a vaccine + hepatitis b vaccine in hepatitis A (HAV) and hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoint: Overall number of subjects reporting at least one grade 3 solicited symptom.
02
Drugs
hepatitis A + hepatitis B vaccinehepatitis a vaccine + hepatitis b vaccine
03
Conditions
hepatitis A (HAV)hepatitis B (HBV)
Beyond the preview
Go deeper on 2015-001515-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001515-12.